Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
rhLWdYfEtA6Cx6BR
Listen
